Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep 26;7(18):5210-5214.
doi: 10.1182/bloodadvances.2023010407.

Hematopoietic stem cell mobilization for allogeneic stem cell transplantation by motixafortide, a novel CXCR4 inhibitor

Zachary D Crees  1 , Michael P Rettig  1 , Asad Bashey  2 , Steven M Devine  3 , Samantha Jaglowski  4 , Fei Wan  1 , Amy Zhou  1 , Melinda Harding  1 , Abi Vainstein-Haras  5 , Ella Sorani  5 , Irit Gliko-Kabir  5 , Brenda J Grossman  6 , Peter Westervelt  1 , John F DiPersio  1 , Geoffrey L Uy  1
Affiliations

Hematopoietic stem cell mobilization for allogeneic stem cell transplantation by motixafortide, a novel CXCR4 inhibitor

Zachary D Crees et al. Blood Adv. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: Z.D.C. received research funding from BioLineRx and holds advisory committee membership at BioLineRx. A.V.-H., E.S., and I.G.-K. are employed at BioLineRx. J.F.D. holds equity stock/ownership at Magenta Therapeutics, WUGEN; receives consulting fees from Incyte and RiverVest Venture Partners; holds a board or advisory committee membership at Cellworks Group, RiverVest Venture Partners, and Magenta; receives research funding from Amphivena Therapeutics, NeoImmune Tech, MacroGenics, Incyte, BioLineRx, and WUGEN; receives speaking fees from Incyte; and holds patents in WUGEN. The remaining authors declare no competing financial interests.

Figures

Figure 1.
Figure 1.
Total HSPC yields, with extended CD34+ HSPC and T-cell immunophenotyping. (A) Total CD34+ HSPC yields in HLA–matched sibling donors mobilized with 1 injection of motixafortide (1.0 mg/kg) and up to 2 LPs. (B) Total CD34+ HSPC yields in HLA–matched sibling donors or haploidentical donors mobilized with 1 injection of motixafortide (1.25 mg/kg) and up to 2 LPs. (C) Inhibition of anti-CXCR4 monoclonal antibody clone 12G5 binding to motixafortide-mobilized CD34+ HSPCs. CXCR4 expression on CD34+ HSPCs obtained from the day 1 apheresis product was determined via flow cytometery, using anti-CXCR4 clones 12G5 and 1D9. (D) Extended HSPC immunophenotyping of CD34+ purified cells from apheresis product mobilized with motixafortide with relative proportions of HSC/CMPs, granulocytic myeloid progenitors and common lymphoid progenitors, and pre-pDCs. (E,G) Pan-mobilization of myeloid and lymphoid subsets by using motixafortide. The PB concentration of each subset was calculated before and 3 hours after BL-804 treatment (before initiation of LP) and relative change calculated. (F,H) The expression of CXCR4 on each subset at baseline was determined via flow cytometry, using anti-CXCR4 clone 12G5.
See this image and copyright information in PMC

References

    1. Anderlini P, Rizzo JD, Nugent ML, et al. Peripheral blood stem cell donation: an analysis from the International Bone Marrow Transplant Registry (IBMTR) and European Group for Blood and Marrow Transplant (EBMT) databases. Bone Marrow Transplant. 2001;27(7):689–692. - PubMed
    1. Moncada V, Bolan C, Yau YY, Leitman SF. Analysis of PBPC cell yields during large-volume leukapheresis of subjects with a poor mobilization response to filgrastim. Transfusion. 2003;43(4):495–501. - PubMed
    1. Abboud M, Laver J, Blau CA. Granulocytosis causing sickle-cell crisis. Lancet. 1998;351(9107):959. - PubMed
    1. Adler BK, Salzman DE, Carabasi MH, Vaughan WP, Reddy VV, Prchal JT. Fatal sickle cell crisis after granulocyte colony-stimulating factor administration. Blood. 2001;97(10):3313–3314. - PubMed
    1. Fitzhugh CD, Hsieh MM, Bolan CD, Saenz C, Tisdale JF. Granulocyte colony-stimulating factor (G-CSF) administration in individuals with sickle cell disease: time for a moratorium? Cytotherapy. 2009;11(4):464–471. - PMC - PubMed

Publication types

MeSH terms